Redifferentiation-facilitated radioiodine therapy in thyroid cancer

in Endocrine-Related Cancer
View More View Less
  • 1 L Lamartina, Nuclear Medicine and Endocrine Oncology, Institut Gustave-Roussy, Villejuif, France
  • 2 N Anizan, 2. Department of Medical Physics, , Institut de Cancerologie Gustave Roussy, Villejuif, France
  • 3 C Dupuy, UMR 8200 CNRS, Gustave Roussy, Villejuif, France
  • 4 S Leboulleux, Nuclear Medicine, Gustave Roussy Institute, Villejuif, France
  • 5 M Schlumberger, Endocrine oncology and nuclear medicine, Gustave Roussy, Villejuif, France

Correspondence: Martin Schlumberger, Email:
Restricted access

Based on experimental data, the inhibition of the MAPkinase pathway in patients with radioiodine refractory thyroid cancer was capable to induce a redifferentiation. Preliminary data obtained on small series of patients are encouraging and this strategy might become an alternative treatment in those patients with a druggable mutation that induces a stimulation of the MAP kinase pathway. This is an active field of research to answer many still unresolved questions.


Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 502 502 104
Full Text Views 40 40 9
PDF Downloads 79 79 16